Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert

iStent inject® trabecular micro-bypass implantation as a stand-alone procedure or in combination with phacoemulsification cataract surgery: 6 month retrospective case review

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Glaucoma

Venue: Poster Village: Pod 2

First Author: : M.Economou SWEDEN

Co Author(s): :    T. Snaebjörnsson Arnljóts                       

Abstract Details


To investigate efficacy and safety of iStent inject as a standalone procedure vs. combined iStent inject and phacoemulsification in eyes with predominantly primary open-angle glaucoma (POAG) and pseudoexfoliative glaucoma (PXG).


The study was conducted at St Erik Eye Hospital at the Karolinska Institute in Stockholm which is a tertiary referral center for glaucoma surgery serving the whole of Sweden.


Retrospective, consecutive case series of all patients with mainly POAG or PXG that underwent iStent inject alone or in combination with cataract surgery from October 2016 to October 2017 with a minimum follow-up of one month. Main study outcomes were IOP reduction, change in visual acuity (VA), number of antiglaucoma medications and complications related to the procedures. All surgeries were carried out by a single experienced surgeon.


Sixteen eyes in the iStent-alone group and 19 eyes in the combined group were included. Mean pre- and postoperative IOPs in the iStent-alone group 20.3 ± 5.1 and 15.9 ± 4.5 mmHg (mean reduction 4.4 ± 3.7 mmHg, p=0.0004); 21.7 ± 5.6 and 15.9 ± 3.1 mmHg in the phaco-iStent group (mean reduction 5.8 ± 4.8 mmHg). Number of antiglaucoma medications was significantly reduced in the combined group (3.0 ± 1.1 to 2.3 ± 1.0 (p=0.0010). No sustained vision-threatening complications were observed. Mean follow-up was 142.3 ± 82.7 in the iStent-alone and 155.4 ± 80.6 days in the combined group.


In this short-term study implantation of iStent inject resulted in a promising and meaningful IOP reduction at the same time demonstrating a highly favorable safety profile. Furthermore, a combined procedure may provide an increasingly larger IOP reduction while simultaneously reducing the antiglaucomatous medication burden of the patients.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented

Back to previous